X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

PhRMA releases 2021 industry profile

By Gabby Migliara  |    September 20, 2021
Today, PhRMA released its 2021 Biopharmaceutical Industry Profile, a resource that highlights the latest from the industry on innovation, access and affordability. The Profile has told the story...   Read More

Addressing data challenges to improve health equity

By Emily Donaldson  |    September 17, 2021
The COVID-19 pandemic has shed light on the ways that systemic racism pervades nearly every facet of life – especially within our health care system. The biopharmaceutical industry is dedicated to...   Read More

America’s biopharmaceutical companies to Congress: Government “negotiation” is the wrong approach

By Stephen J. Ubl  |    September 15, 2021
Today, PhRMA member companies made public an open letter to Capitol Hill to encourage Congress to abandon old partisan ideas on drug pricing and instead pursue policies that actually address what...   Read More

A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19

By Joseph Havey  |    September 8, 2021
Since the start of the pandemic, America’s biopharmaceutical companies have worked around the clock to research, develop and manufacture treatments and vaccines to fight COVID-19. Already, we’ve...   Read More

Patients and innovators lose if the government pursues ‘march-in’

By Megan Van Etten  |    September 7, 2021
The Biden Administration this summer issued an executive order that seems to endorse the use of “march-in” – when the government seizes patent rights from an innovator to let competitors use that...   Read More

The impact of monoclonal antibodies and COVID-19 recovery

By Andrew Powaleny  |    September 2, 2021
As the United States and world continue to fight the COVID-19 pandemic, America’s biopharmaceutical research companies continue to do our part in fighting this deadly virus. Decades of scientific...   Read More

Recent polling misrepresents public support for Medicare “negotiation”

By Tom Wilbur  |    August 31, 2021
Proponents of government price setting often misrepresent voters’ opinions on support for allowing the federal government to “negotiate” drug prices. This includes recent polling from advocacy...   Read More

Recognizing National Immunization Awareness Month

By Richard Moscicki, M.D.  |    August 31, 2021
Vaccines have played a critical role in reducing the spread of, and in some cases, eliminating the threat of many devastating infectious diseases. They are often cited as second only to clean...   Read More

What they’re saying: Patient advocates want to protect Medicare from government interference

By Gabby Migliara  |    August 24, 2021
For seniors and people with disabilities, Medicare Parts B and D provide important access to lifesaving medicines. Unfortunately, some in Congress are proposing changes to Medicare under the guise...   Read More

Driving further innovation is critical to global vaccine equity

By Megan Van Etten  |    August 24, 2021
The following is part of a series of Catalyst posts detailing each of the five strategies to advance COVID-19 global vaccine equity – which rely on and benefit from a strong innovation ecosystem.   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates